Synthon has successfully transitioned ownership from BC Partners to Goldman Sachs Alternatives, with plans for continued growth in the complex generics sector.

Information on the Target

Synthon, headquartered in the Netherlands, is a prominent global player in the development and manufacturing of complex generic pharmaceuticals. With a strong presence across eight countries, Synthon operates four research and development laboratories and four manufacturing facilities located in Spain, the Czech Republic, Argentina, and Chile. The company is particularly known for its expertise in creating generic versions of complicated medications, including those used in the treatment of cancer, cardiovascular diseases, and multiple sclerosis.

The organization focuses on providing high-quality, affordable alternatives to original branded drugs, thereby contributing significantly to patient access to essential health treatments. By maintaining a vertically integrated structure, Synthon ensures quality control throughout the production process, reinforcing its position as a leader in the pharmaceuticals industry.

Industry Overview in the Netherlands

The pharmaceutical industry in the Netherlands is robust and innovative, characterized by a mix of globally recognized companies and dynamic startups. The country benefits from a favorable regulatory environment and strong government supp